EUDA Health Holdings Announces Proposed Merger with TheoremRx Inc. to Advance Biopharma Treatments

Singapore-based digital health platform, EUDA Health Holdings Limited, has signed a letter of intent for a proposed merger with TheoremRx Inc., a U.S.-based company focused on developing new treatments for cancer and women’s health conditions. The merger aims to combine the strengths of both companies’ platforms to advance critical biopharma treatments and create significant value for shareholders.

The letter of intent includes a 30-day exclusivity period, extendable by an additional 15 days, during which EUDA and TheoremRx will negotiate and conduct due diligence to reach a definitive agreement. The merger would involve TheoremRx merging with a subsidiary of EUDA, with the legal structure, ownership stake, and name and branding to be determined through mutual agreement.

Dr. Kelvin Chen, Founder and CEO of EUDA, expressed excitement about the proposed merger, stating that it presents an opportunity for EUDA to strengthen its market position and leverage TheoremRx’s access to capital and robust pipeline of compounds. TheoremRx’s portfolio focuses on high-demand unmet therapeutic areas, with minimal time and cost required to reach key monetization milestones.

The completion of the merger is subject to various conditions, including negotiation of a definitive agreement, regulatory approvals, and customary closing conditions. While there can be no assurance that the merger will be completed or that the proposed terms will remain unchanged, both companies are optimistic about the potential for enhanced outcomes in personalized healthcare.

EUDA Health Holdings Limited operates a digital healthcare ecosystem in Southeast Asia, aiming to make healthcare more affordable and accessible while improving patient experiences. Their proprietary unified AI platform assesses medical history, connects patients with clinicians, and predicts optimal treatment outcomes.

TheoremRx Inc., headquartered in the United States, focuses on developing new treatments with safe administration, low toxicity, and high potential for polypharmacy usage in cancer and women’s health conditions. The company’s portfolio includes substantially de-risked clinical programs in oncology and women’s health, with a strong emphasis on reducing clinical risk and time to value.

As EUDA Health Holdings and TheoremRx move forward with the merger process, they anticipate significant advancements in biopharma treatments and a positive impact on the healthcare industry.